Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base

Killelea, Brigid K.; Yang, Vicky Q.; Wang, Shi Yi; Hayse, Brandon; Mougalian, Sarah Schellhorn; Horowitz, Nina; Chagpar, Anees B.; Pusztai, Lajos; Lannin, Donald R.

doi:10.1200/jco.2015.63.7801

Cited by 91 publications

(84 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current treatment modalities for TNBC are limited to surgery, radiation and systemic chemotherapy because of the lack of more specific therapeutic targets [17]. Over the past few decades, tremendous efforts have been expended in searching for a molecular targeted therapy for TNBC and with limited success [18]. In this study, we found that high expression of Prrx1b was closely related with adverse clinicopathological parameters of TNBC, including tumour size and vascular invasion, indicating that Prrx1b might participate in the development of TNBC.…”

Section: Discussionmentioning

confidence: 99%

RETRACTED: Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial–mesenchymal transition in triple‐negative breast cancer

Zhao

Liu

et al. 2016

J Cellular Molecular Medi

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a highly aggressive tumour subtype associated with poor prognosis. The mechanisms involved in TNBC progression remains largely unknown. To date, there are no effective therapeutic targets for this tumour subtype. Paired-related homeobox 1b (Prrx1b), one of major isoforms of Prrx1, has been identified as a new epithelial-mesenchymal transition (EMT) inducer. However, the function of Prrx1b in TNBC has not been elucidated. In this study, we found that Prrx1b was significantly up-regulated in TNBC and associated with tumour size and vascular invasion of breast cancer. Silencing of Prrx1b suppressed the proliferation, migration and invasion of basal-like cancer cells. Moreover, silencing of Prrx1b prevented Wnt/b-catenin signaling pathway and induced the mesenchymal-epithelial transition (MET). Taken together, our data indicated that Prrx1b may be an important regulator of EMT in TNBC cells and a new therapeutic target for interventions against TNBC invasion and metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED: Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial–mesenchymal transition in triple‐negative breast cancer

Zhao

Liu

et al. 2016

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Chemotherapy was given more frequently to black, Hispanic and Asian women than to white women (p > 0.001), an association probably related to higher rates of advanced stages, high grade as well as TNBC and HER2 + tumors in these women. Black patients had a lower pCR rate for TNBC and HER2 + tumors than white [86]. Recently, Warner et al evaluated the impact of ethnic group and BMI on achievement of pCR after neoadjuvant chemotherapy in 1797 women with BC, including black (14.1%), Hispanic (11.1%), overweight (28.9%) and obese (41.4%) -blacks and Hispanics were more likely to be obese than whites, however, ethnicity was not a significant predictor of pCR (Hispanic vs non-Hispanic: OR: 1.30; 95% CI: 0.67-2.53) [67].…”

Section: Differences In Response and Tolerance To Treatment Chemotherapymentioning

confidence: 90%

“…Killelea et al retrospectively evaluated 127,417 patients with known ethnic group information from the American National Cancer Database who received chemotherapy, including 27,300 in the neoadjuvant setting [86]. Chemotherapy was given more frequently to black, Hispanic and Asian women than to white women (p > 0.001), an association probably related to higher rates of advanced stages, high grade as well as TNBC and HER2 + tumors in these women.…”

Section: Differences In Response and Tolerance To Treatment Chemotherapymentioning

confidence: 99%

Genetics, Tumor Features and Treatment Response of Breast Cancer in Latinas

Castañeda

Castillo

Villarreal‐Garza

et al. 2018

Breast Cancer Manag.

View full text Add to dashboard Cite

Practice pointsr Latinas with breast cancer have been associated with lower prevalence and higher mortality rates. r The access to healthcare system for Latinas has been described as lower than for white women. r Rates of grade III and triple-negative phenotype breast cancer are higher for Latinas than for white women. r BRCA mutation prevalence appears to be higher in Latinas than white women in the American population. r Distribution of BRCA mutation differs by country in Central, Latin America or Caribbean and recurrent mutations have been described in Mexico. r Finally, evaluated information about treatment efficacy and toxicity in Latinas with breast cancer indicate similar effects than in the white race.Breast cancer is a heterogeneous and genetic disease that has variability according to ethnicity and race with respect to incidence, clinical characteristics and prognosis. The incidence of breast cancer is lower but mortality is higher in Latinas than Caucasians in the US series. Risk factors appear to have different prevalence and impact in Latinas. Breast cancer in Latinas has particular clinic-pathological features including younger age, higher rates of triple-negative subtype and advanced stages. Molecular studies find that Latinas from every region have a specific BRCA incidence and a recurrent mutation, as well as differences in activity of molecular pathways. Treatment response rates and toxicity have also been compared, and no difference was found between Latinas and other ethnic groups.

show abstract

“…27 Further investigation is needed to elucidate the factors associated with more frequent utilization of neoadjuvant chemotherapy in black patients, which may be multifactorial. These factors may include socioeconomic status, educational and cultural background, nutritional status, medical comorbidities not captured by the CCI, performance status, access to a primary care physician, and frequency of diagnosis in an emergency department rather than an outpatient setting.…”

Section: Discussionmentioning

confidence: 99%

Racial Differences in Survival From Epithelial Ovarian Cancer Are Associated With Stage at Diagnosis and Use of Neoadjuvant Therapy: A 10-Year Single-Institution Experience With a Racially Diverse Urban Population

Miller

Tymon‐Rosario

Strickler

et al. 2018

Int J Gynecol Cancer

View full text Add to dashboard Cite

In a racially/ethnically diverse population with ovarian cancer, black women had poorer disease-free survival than whites, although this was statistically accounted for by stage at diagnosis and use of neoadjuvant therapy. Research is needed to determine how differences in access/utilization of care and genetic differences in tumor biology may impact late stage diagnosis and use of neoadjuvant chemotherapy among black ovarian cancer patients.

show abstract

Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base

Cited by 91 publications

References 18 publications

RETRACTED: Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial–mesenchymal transition in triple‐negative breast cancer

RETRACTED: Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial–mesenchymal transition in triple‐negative breast cancer

Genetics, Tumor Features and Treatment Response of Breast Cancer in Latinas

Racial Differences in Survival From Epithelial Ovarian Cancer Are Associated With Stage at Diagnosis and Use of Neoadjuvant Therapy: A 10-Year Single-Institution Experience With a Racially Diverse Urban Population

Contact Info

Product

Resources

About